<DOC>
	<DOCNO>NCT01697384</DOCNO>
	<brief_summary>Objective evaluate efficacy safety histrelin acetate subdermal implant ( originally versus Lupron Depot-3 Month ) male patient advanced prostate cancer 52 week treatment implant . After consultation w/ FDA , design modify eliminate Lupron arm continue study open-label non-randomized study . Primary endpoint testosterone suppression , assessed percent patient whose testosterone indicate chemical castration level ( &lt; =50 ng/dL ) 52 week treatment implant .</brief_summary>
	<brief_title>Study Evaluate Efficacy Safety Histrelin Subdermal Implant Men With Advanced Prostate Cancer</brief_title>
	<detailed_description>Other outcome measure include serum level LH , PSA , well non-clinical assessment , eg , WHO Performance Status , pain level assessment , quality life questionnaire . Safety evaluate via adverse event , vital sign , clinical laboratory outcome , physical examination , ECGs . Local tolerability outcome also evaluate . An extension period study include annual replacement implant implant approve FDA ( October 12 , 2004 ) . Efficacy safety follow extension period .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<criteria>Key Male Age 45 old Histologically confirm adenocarcinoma prostate Disease Staging III IV Clinical indication androgen suppression therapy Serum testosterone least 150 ng/dL screening WHO Performance Scale 0 3 Life expectancy least one year Key Bilateral orchiectomy Prior androgenablative therapy within past year Second malignancy 5 year ( except adequately treat nonmelanomatous skin cancer superficial bladder cancer ) Spinal cord compression</criteria>
	<gender>Male</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>prostate cancer , PSA</keyword>
</DOC>